生殖细胞肿瘤的新型生物标志物微小RNA - 371a - 3p在临床1期患者中衰减非常迅速。
The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
作者信息
Radtke Arlo, Hennig Finja, Ikogho Raphael, Hammel Johannes, Anheuser Petra, Wülfing Christian, Belge Gazanfer, Dieckmann Klaus-Peter
机构信息
Faculty of Biology and Chemistry, University of Bremen, Bremen, Germany.
Department of Urology, Albertinen Krankenhaus, Hamburg, Germany.
出版信息
Urol Int. 2018;100(4):470-475. doi: 10.1159/000488771. Epub 2018 Apr 26.
BACKGROUND
Accumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment.
PATIENTS AND METHODS
Twenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods.
RESULTS
Serum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size.
CONCLUSIONS
Serum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
背景
越来越多的证据表明，血清微小RNA（miR）-371a-3p水平是睾丸生殖细胞肿瘤（GCT）的一种新型肿瘤标志物。目前，关于血清水平对治疗反应的下降速度的信息有限。
患者与方法
24例临床分期为1期的睾丸GCT患者（20例精原细胞瘤，4例非精原细胞瘤，中位年龄40岁）在术前及术后3天内多次测量血清miR-371a-3p水平。3例患者在术后24小时内进行了额外检测。采用描述性统计方法分析测量结果。
结果
血清水平在1天、2天和3天内分别降至术前水平的2.62%、1.27%和0.47%。计算得出的半衰期为3.7 - 7小时。衰减速度与肿瘤大小显著相关。
结论
miR-371a-3p的血清水平半衰期短，小于12小时。治疗后迅速衰减是一个有价值的特征，证实了miR-371a-3p作为GCT有价值血清生物标志物的有用性。
Zotero 插件